NanoViricides(US:NNVC) Proactive Investorsยท2024-05-13 19:21Core Insights - NanoViricides has released new data supporting the safety and broad antiviral activity of its investigational therapeutic NV-387 against multiple viruses, including coronaviruses, RSV, and influenza A viruses [1][4] Group 1: Antiviral Efficacy - NV-387 demonstrated substantially superior antiviral effects in a lethal animal model of lung infection caused by Influenza A/H3N2 compared to three approved anti-influenza drugs: Oseltamivir, Peramivir, and Baloxivir [2] - The drug was effective against the orthopoxvirus family, including Smallpox and Mpox, in both inhalation and skin abrasion transmission modes [2] - In a model for Smallpox and Mpox infection, NV-387 increased the lifespan of mice comparably to the approved Smallpox drug tecovirimat [3] Group 2: Clinical Trials and Development - The company has completed Phase 1 clinical trials for NV-387 in healthy subjects with no adverse events, indicating safety for progression to Phase 2 [4] - NV-387 will advance into Phase 2 trials specifically for RSV, which currently has no treatment options [5] - The drug has shown superior efficacy in extending survival in animal models compared to existing approved drugs for influenza [5] Group 3: Strategic Importance - The development of NV-387 against Smallpox is significant due to concerns about the potential for viral escape from existing treatments like tecovirimat [6] - The combination of NV-387 and tecovirimat showed improved effects, suggesting a strong potential for developing a new drug against Smallpox [7] - The timeline for clinical trials is dependent on regulatory processes, although the company is prepared to proceed [8]